blank
blank

Human genomics technologies in clinical studies – the research landscape: report on the 1990–2024 period

1:1
Published on 14 December, this WHO technical document maps global trends in registered clinical studies using human genomic technologies from 1990 to 2024, including patterns of inclusion and equity.

This WHO snapshot provides a global overview of clinical studies involving human genomic technologies registered between 1990 and 2024. It summarises how research activity has evolved over time and examines patterns in growth, disease focus, geographical distribution and population inclusion, with specific attention to equity of participation. The report is intended to inform stakeholders about the current landscape of genomics in clinical research and where gaps or imbalances may remain.

Acces this publication
Scientific paper

Year of publication

2025

Source

World Health Organization (WHO) (Technical document; WHO Team: Research for Health (RFH))

Author

WHO Team: Research for Health (RFH)

You might also be interested in

Open Academy

Open Academy x ERDERA Schools return to Barcelona to strengthen rare disease research participation

From 25–28 May in Barcelona, the EURORDIS-led Open Academy x ERDERA Schools will bring patient advocates and early-career researchers together for four days of rare disease training, exchange and peer learning.
Copia de ERDERA training and announcements template

Advancing Rare Disease Diagnostics: The ERDERA Diagnostic Research Workstream Webinar Series

A new online learning series for ERN professionals, clinicians, researchers, and stakeholders.
Copia de ERDERA training and announcements template

Webinar: The ERDERA Diagnostic Research Workstream – An overview

The session will introduce the workstream’s activities in data sharing, systematic diagnostic reanalysis, advanced diagnostic pipelines, and genomic and multi-omics innovation.
stocksnap-people-2574170_1920

EMA launches consultation on proof-of-concept data in paediatric oncology

This initiative is also highly relevant from a rare diseases perspective, as paediatric cancers are rare conditions where small patient populations make robust non‑clinical proof‑of‑concept data essential for responsible and ethical trial initiation.

ERDERA's

search form